Malik Kahook
Concepts (455)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 63 | 2025 | 250 | 14.280 |
Why?
| | Intraocular Pressure | 72 | 2025 | 327 | 9.540 |
Why?
| | Glaucoma, Open-Angle | 29 | 2024 | 104 | 6.460 |
Why?
| | Trabecular Meshwork | 23 | 2019 | 80 | 5.200 |
Why?
| | Glaucoma Drainage Implants | 18 | 2022 | 46 | 4.850 |
Why?
| | Antihypertensive Agents | 27 | 2019 | 509 | 4.370 |
Why?
| | Trabeculectomy | 17 | 2025 | 75 | 4.040 |
Why?
| | Preservatives, Pharmaceutical | 12 | 2024 | 26 | 3.770 |
Why?
| | Angiogenesis Inhibitors | 15 | 2021 | 236 | 3.480 |
Why?
| | Ocular Hypertension | 18 | 2024 | 70 | 3.360 |
Why?
| | Conjunctiva | 13 | 2012 | 53 | 3.100 |
Why?
| | Filtering Surgery | 9 | 2016 | 23 | 3.090 |
Why?
| | Ophthalmic Solutions | 18 | 2024 | 79 | 3.010 |
Why?
| | Benzalkonium Compounds | 11 | 2024 | 15 | 2.580 |
Why?
| | Tonometry, Ocular | 24 | 2025 | 103 | 2.410 |
Why?
| | Vascular Endothelial Growth Factor A | 12 | 2021 | 557 | 2.280 |
Why?
| | Phacoemulsification | 14 | 2025 | 122 | 2.240 |
Why?
| | Timolol | 8 | 2019 | 14 | 2.170 |
Why?
| | Prostaglandins F, Synthetic | 8 | 2014 | 9 | 2.160 |
Why?
| | Ciliary Body | 12 | 2025 | 40 | 2.020 |
Why?
| | Glaucoma, Neovascular | 5 | 2015 | 10 | 1.670 |
Why?
| | Cloprostenol | 9 | 2013 | 13 | 1.650 |
Why?
| | Laser Coagulation | 10 | 2025 | 77 | 1.550 |
Why?
| | Lens Implantation, Intraocular | 7 | 2020 | 80 | 1.320 |
Why?
| | Cataract Extraction | 6 | 2020 | 119 | 1.300 |
Why?
| | Cataract | 8 | 2020 | 238 | 1.290 |
Why?
| | Prosthesis Implantation | 8 | 2022 | 153 | 1.280 |
Why?
| | Antibodies, Monoclonal | 11 | 2011 | 1519 | 1.260 |
Why?
| | Optic Disk | 7 | 2025 | 53 | 1.250 |
Why?
| | Cornea | 8 | 2013 | 155 | 1.230 |
Why?
| | Tomography, Optical Coherence | 7 | 2025 | 264 | 1.220 |
Why?
| | Retinal Ganglion Cells | 6 | 2025 | 121 | 1.170 |
Why?
| | Drug Delivery Systems | 7 | 2019 | 379 | 1.150 |
Why?
| | Blister | 4 | 2012 | 39 | 1.150 |
Why?
| | Stents | 5 | 2021 | 556 | 1.090 |
Why?
| | Travoprost | 10 | 2014 | 13 | 1.090 |
Why?
| | Medication Adherence | 4 | 2016 | 512 | 1.050 |
Why?
| | Nerve Fibers | 4 | 2012 | 104 | 1.050 |
Why?
| | Optic Nerve Diseases | 3 | 2025 | 49 | 1.010 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2019 | 192 | 1.010 |
Why?
| | Humans | 135 | 2026 | 144261 | 0.990 |
Why?
| | Sulfonamides | 4 | 2018 | 580 | 0.980 |
Why?
| | Glaucoma, Angle-Closure | 5 | 2018 | 23 | 0.970 |
Why?
| | Endoscopy | 8 | 2025 | 315 | 0.970 |
Why?
| | Lenses, Intraocular | 4 | 2020 | 49 | 0.950 |
Why?
| | Corneal Diseases | 2 | 2024 | 46 | 0.950 |
Why?
| | Lens, Crystalline | 2 | 2020 | 136 | 0.930 |
Why?
| | Capsulorhexis | 2 | 2016 | 9 | 0.920 |
Why?
| | Eye | 6 | 2013 | 109 | 0.890 |
Why?
| | Polymers | 5 | 2011 | 498 | 0.880 |
Why?
| | Macular Degeneration | 4 | 2010 | 191 | 0.860 |
Why?
| | Microscopy | 4 | 2018 | 156 | 0.850 |
Why?
| | Photons | 4 | 2016 | 76 | 0.850 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 109 | 0.820 |
Why?
| | Dry Eye Syndromes | 1 | 2024 | 56 | 0.790 |
Why?
| | Pilocarpine | 2 | 2025 | 16 | 0.790 |
Why?
| | Vision Disorders | 4 | 2025 | 178 | 0.780 |
Why?
| | Ophthalmologic Surgical Procedures | 4 | 2014 | 90 | 0.760 |
Why?
| | Cell Survival | 8 | 2013 | 1098 | 0.760 |
Why?
| | Brimonidine Tartrate | 3 | 2018 | 10 | 0.730 |
Why?
| | Aged | 45 | 2025 | 25850 | 0.730 |
Why?
| | Bevacizumab | 12 | 2021 | 167 | 0.710 |
Why?
| | Drug Packaging | 4 | 2015 | 41 | 0.710 |
Why?
| | Visual Acuity | 12 | 2025 | 486 | 0.700 |
Why?
| | Recombinant Fusion Proteins | 2 | 2015 | 674 | 0.690 |
Why?
| | Antibodies, Monoclonal, Humanized | 12 | 2011 | 985 | 0.660 |
Why?
| | Thiazines | 2 | 2018 | 13 | 0.650 |
Why?
| | Laser Therapy | 3 | 2016 | 135 | 0.650 |
Why?
| | Spectrum Analysis, Raman | 4 | 2013 | 41 | 0.640 |
Why?
| | Epithelium, Corneal | 2 | 2010 | 41 | 0.640 |
Why?
| | Visual Fields | 4 | 2025 | 115 | 0.630 |
Why?
| | Prosthesis Design | 4 | 2016 | 354 | 0.630 |
Why?
| | Thiophenes | 2 | 2011 | 128 | 0.620 |
Why?
| | Sclera | 7 | 2015 | 38 | 0.620 |
Why?
| | Drug Combinations | 9 | 2017 | 390 | 0.610 |
Why?
| | Microscopy, Fluorescence, Multiphoton | 8 | 2016 | 69 | 0.600 |
Why?
| | beta-Alanine | 1 | 2019 | 23 | 0.580 |
Why?
| | Benzoates | 1 | 2019 | 50 | 0.580 |
Why?
| | Middle Aged | 43 | 2025 | 35762 | 0.570 |
Why?
| | Imaging, Three-Dimensional | 5 | 2016 | 582 | 0.560 |
Why?
| | rho-Associated Kinases | 1 | 2019 | 83 | 0.550 |
Why?
| | Aged, 80 and over | 21 | 2025 | 8243 | 0.550 |
Why?
| | Drug Monitoring | 3 | 2016 | 389 | 0.550 |
Why?
| | Ranibizumab | 8 | 2021 | 21 | 0.550 |
Why?
| | Cells, Cultured | 12 | 2015 | 4146 | 0.540 |
Why?
| | Ophthalmology | 5 | 2024 | 116 | 0.530 |
Why?
| | Ocular Hypotension | 4 | 2022 | 10 | 0.530 |
Why?
| | Retinal Pigment Epithelium | 4 | 2015 | 80 | 0.520 |
Why?
| | Male | 57 | 2025 | 72035 | 0.520 |
Why?
| | Treatment Outcome | 20 | 2025 | 11643 | 0.520 |
Why?
| | Prostaglandins F | 3 | 2011 | 15 | 0.510 |
Why?
| | Equipment Design | 6 | 2018 | 530 | 0.510 |
Why?
| | Anterior Capsule of the Lens | 1 | 2016 | 2 | 0.500 |
Why?
| | Patient Compliance | 4 | 2018 | 585 | 0.480 |
Why?
| | Epithelial Cells | 3 | 2011 | 1125 | 0.480 |
Why?
| | Retrospective Studies | 28 | 2025 | 17009 | 0.480 |
Why?
| | Prospective Studies | 14 | 2021 | 7970 | 0.470 |
Why?
| | Female | 54 | 2025 | 77976 | 0.460 |
Why?
| | Intravitreal Injections | 6 | 2021 | 71 | 0.460 |
Why?
| | Reminder Systems | 1 | 2016 | 141 | 0.450 |
Why?
| | Oxidative Stress | 2 | 2013 | 1339 | 0.450 |
Why?
| | Wound Healing | 3 | 2012 | 351 | 0.440 |
Why?
| | Mitomycin | 3 | 2016 | 32 | 0.440 |
Why?
| | Uveitis | 3 | 2022 | 148 | 0.440 |
Why?
| | Diabetic Retinopathy | 2 | 2023 | 207 | 0.440 |
Why?
| | Motivational Interviewing | 1 | 2016 | 116 | 0.440 |
Why?
| | Pharmaceutical Preparations | 2 | 2019 | 169 | 0.430 |
Why?
| | Circadian Rhythm | 3 | 2023 | 513 | 0.430 |
Why?
| | Iris | 4 | 2013 | 24 | 0.410 |
Why?
| | Behavior Therapy | 1 | 2016 | 281 | 0.400 |
Why?
| | Follow-Up Studies | 12 | 2025 | 5389 | 0.400 |
Why?
| | Injections | 6 | 2010 | 196 | 0.400 |
Why?
| | Pyruvates | 1 | 2013 | 24 | 0.400 |
Why?
| | Administration, Topical | 5 | 2016 | 150 | 0.400 |
Why?
| | Cell Count | 4 | 2021 | 320 | 0.400 |
Why?
| | Patient Preference | 1 | 2016 | 221 | 0.390 |
Why?
| | Stainless Steel | 2 | 2010 | 21 | 0.390 |
Why?
| | Porphyrins | 1 | 2013 | 16 | 0.390 |
Why?
| | Pseudophakia | 2 | 2018 | 22 | 0.390 |
Why?
| | Triamcinolone Acetonide | 2 | 2014 | 19 | 0.380 |
Why?
| | Anterior Chamber | 2 | 2012 | 27 | 0.380 |
Why?
| | Perception | 3 | 2021 | 377 | 0.380 |
Why?
| | Goblet Cells | 2 | 2012 | 22 | 0.370 |
Why?
| | Photosensitizing Agents | 1 | 2013 | 42 | 0.370 |
Why?
| | Image Processing, Computer-Assisted | 4 | 2026 | 780 | 0.370 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2011 | 2026 | 0.370 |
Why?
| | Health Behavior | 2 | 2015 | 782 | 0.360 |
Why?
| | Rabbits | 7 | 2015 | 648 | 0.360 |
Why?
| | Eye Diseases | 3 | 2024 | 94 | 0.360 |
Why?
| | Drugs, Generic | 1 | 2011 | 27 | 0.350 |
Why?
| | Vitreous Body | 5 | 2010 | 116 | 0.340 |
Why?
| | Telemedicine | 1 | 2021 | 940 | 0.340 |
Why?
| | Drug Therapy | 1 | 2011 | 80 | 0.340 |
Why?
| | Surgically-Created Structures | 1 | 2011 | 2 | 0.340 |
Why?
| | NADP | 1 | 2011 | 55 | 0.340 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.330 |
Why?
| | Blood Pressure | 2 | 2017 | 1759 | 0.330 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2010 | 20 | 0.320 |
Why?
| | Tissue Adhesives | 2 | 2010 | 22 | 0.320 |
Why?
| | Prescription Drugs | 1 | 2011 | 110 | 0.310 |
Why?
| | Endothelins | 1 | 2010 | 63 | 0.310 |
Why?
| | Choroid | 1 | 2010 | 79 | 0.310 |
Why?
| | Wet Macular Degeneration | 1 | 2010 | 57 | 0.310 |
Why?
| | Dexamethasone | 1 | 2012 | 370 | 0.300 |
Why?
| | Quinoxalines | 1 | 2009 | 65 | 0.300 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 336 | 0.300 |
Why?
| | Artificial Intelligence | 2 | 2025 | 365 | 0.290 |
Why?
| | Depressive Disorder | 1 | 2012 | 374 | 0.290 |
Why?
| | In Vitro Techniques | 4 | 2011 | 1047 | 0.290 |
Why?
| | Adult | 21 | 2025 | 40262 | 0.290 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 242 | 0.290 |
Why?
| | Anxiety Disorders | 1 | 2012 | 368 | 0.280 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2020 | 53 | 0.280 |
Why?
| | Surgical Wound Dehiscence | 1 | 2008 | 19 | 0.280 |
Why?
| | Collagen | 5 | 2016 | 455 | 0.270 |
Why?
| | Primary Health Care | 2 | 2009 | 1710 | 0.270 |
Why?
| | Particulate Matter | 2 | 2011 | 347 | 0.270 |
Why?
| | Reproducibility of Results | 8 | 2025 | 3403 | 0.270 |
Why?
| | Aqueous Humor | 4 | 2016 | 38 | 0.270 |
Why?
| | Cognition Disorders | 1 | 2012 | 537 | 0.270 |
Why?
| | Postoperative Period | 5 | 2025 | 353 | 0.260 |
Why?
| | Neovascularization, Pathologic | 4 | 2013 | 286 | 0.260 |
Why?
| | Retinoschisis | 1 | 2006 | 2 | 0.260 |
Why?
| | Software | 1 | 2012 | 690 | 0.250 |
Why?
| | Endothelium, Corneal | 2 | 2021 | 19 | 0.250 |
Why?
| | Fluorescence | 3 | 2011 | 161 | 0.250 |
Why?
| | Trypan Blue | 1 | 2006 | 5 | 0.250 |
Why?
| | Self Administration | 1 | 2007 | 124 | 0.250 |
Why?
| | Animals | 22 | 2016 | 38030 | 0.240 |
Why?
| | Carbohydrate Metabolism, Inborn Errors | 1 | 2006 | 3 | 0.240 |
Why?
| | Coloring Agents | 1 | 2006 | 93 | 0.240 |
Why?
| | Optic Nerve | 1 | 2006 | 66 | 0.240 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1409 | 0.240 |
Why?
| | Administration, Ophthalmic | 2 | 2019 | 16 | 0.230 |
Why?
| | Postoperative Complications | 7 | 2021 | 2916 | 0.230 |
Why?
| | Eye Injuries | 2 | 2006 | 53 | 0.230 |
Why?
| | Visual Field Tests | 2 | 2024 | 32 | 0.230 |
Why?
| | Iridectomy | 1 | 2005 | 2 | 0.230 |
Why?
| | Contact Lenses | 3 | 2020 | 12 | 0.230 |
Why?
| | Retinal Degeneration | 1 | 2006 | 40 | 0.230 |
Why?
| | Acrylic Resins | 2 | 2016 | 45 | 0.230 |
Why?
| | Pseudotumor Cerebri | 1 | 2006 | 32 | 0.230 |
Why?
| | Monitoring, Physiologic | 2 | 2018 | 289 | 0.230 |
Why?
| | Histological Techniques | 2 | 2018 | 38 | 0.230 |
Why?
| | Glucocorticoids | 2 | 2016 | 533 | 0.220 |
Why?
| | Visual Pathways | 1 | 2025 | 61 | 0.220 |
Why?
| | Cadaver | 3 | 2016 | 304 | 0.220 |
Why?
| | Geographic Atrophy | 1 | 2026 | 97 | 0.210 |
Why?
| | Pilot Projects | 5 | 2018 | 1867 | 0.210 |
Why?
| | Alkylating Agents | 3 | 2016 | 24 | 0.210 |
Why?
| | United States Food and Drug Administration | 2 | 2015 | 203 | 0.200 |
Why?
| | Retina | 3 | 2016 | 323 | 0.200 |
Why?
| | Case-Control Studies | 5 | 2024 | 3592 | 0.200 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 6021 | 0.190 |
Why?
| | Drug Stability | 3 | 2011 | 164 | 0.190 |
Why?
| | Prostaglandins, Synthetic | 2 | 2013 | 5 | 0.190 |
Why?
| | Titanium | 2 | 2014 | 81 | 0.190 |
Why?
| | ROC Curve | 1 | 2024 | 612 | 0.180 |
Why?
| | Wounds, Nonpenetrating | 1 | 2005 | 316 | 0.180 |
Why?
| | Nervous System Diseases | 1 | 2024 | 282 | 0.170 |
Why?
| | Drug Storage | 2 | 2011 | 53 | 0.170 |
Why?
| | Heart Rate | 2 | 2017 | 849 | 0.170 |
Why?
| | Self Report | 2 | 2016 | 863 | 0.170 |
Why?
| | Cross-Sectional Studies | 7 | 2022 | 5813 | 0.170 |
Why?
| | Young Adult | 8 | 2019 | 13990 | 0.150 |
Why?
| | Legislation, Drug | 1 | 2020 | 73 | 0.150 |
Why?
| | Specialization | 1 | 2020 | 134 | 0.150 |
Why?
| | Remote Sensing Technology | 1 | 2019 | 19 | 0.140 |
Why?
| | Attitude | 1 | 2021 | 259 | 0.140 |
Why?
| | Postoperative Care | 3 | 2025 | 288 | 0.140 |
Why?
| | Limbus Corneae | 2 | 2015 | 8 | 0.140 |
Why?
| | Biosensing Techniques | 1 | 2020 | 139 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2020 | 123 | 0.140 |
Why?
| | Medication Errors | 2 | 2015 | 83 | 0.130 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 27 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3857 | 0.130 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 250 | 0.130 |
Why?
| | Fibroblasts | 2 | 2013 | 1032 | 0.130 |
Why?
| | Double-Blind Method | 2 | 2019 | 2025 | 0.130 |
Why?
| | Tropicamide | 1 | 2016 | 2 | 0.130 |
Why?
| | Mydriatics | 1 | 2016 | 10 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2020 | 250 | 0.120 |
Why?
| | Phenylephrine | 1 | 2016 | 75 | 0.120 |
Why?
| | Marijuana Use | 1 | 2020 | 213 | 0.120 |
Why?
| | Delayed-Action Preparations | 2 | 2018 | 183 | 0.120 |
Why?
| | Endophthalmitis | 1 | 2016 | 45 | 0.120 |
Why?
| | Fibrosis | 1 | 2018 | 547 | 0.120 |
Why?
| | Artificial Lens Implant Migration | 1 | 2015 | 3 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 643 | 0.110 |
Why?
| | Hyaluronic Acid | 2 | 2008 | 208 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 741 | 0.110 |
Why?
| | Swine | 3 | 2013 | 831 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 484 | 0.110 |
Why?
| | Surgical Flaps | 1 | 2016 | 142 | 0.110 |
Why?
| | Alloys | 1 | 2015 | 38 | 0.110 |
Why?
| | Capsule Opacification | 1 | 2015 | 22 | 0.110 |
Why?
| | Combined Modality Therapy | 2 | 2010 | 1264 | 0.110 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 11 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1092 | 0.110 |
Why?
| | Biodegradable Plastics | 1 | 2014 | 3 | 0.110 |
Why?
| | Endpoint Determination | 1 | 2015 | 83 | 0.110 |
Why?
| | Endothelial Cells | 1 | 2021 | 869 | 0.110 |
Why?
| | Micelles | 1 | 2014 | 40 | 0.110 |
Why?
| | Viscosupplements | 1 | 2014 | 11 | 0.110 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1044 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2012 | 2494 | 0.100 |
Why?
| | Autopsy | 2 | 2011 | 94 | 0.100 |
Why?
| | Nickel | 1 | 2014 | 64 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 2 | 2018 | 878 | 0.100 |
Why?
| | Societies, Medical | 2 | 2015 | 886 | 0.100 |
Why?
| | Disease Progression | 3 | 2024 | 2840 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 338 | 0.100 |
Why?
| | Drug Synergism | 1 | 2014 | 357 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 938 | 0.100 |
Why?
| | Gonioscopy | 1 | 2013 | 12 | 0.100 |
Why?
| | Models, Psychological | 1 | 2015 | 296 | 0.100 |
Why?
| | Protective Agents | 1 | 2013 | 42 | 0.100 |
Why?
| | Macular Edema | 2 | 2016 | 48 | 0.100 |
Why?
| | Neuroprotective Agents | 1 | 2014 | 143 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2019 | 847 | 0.100 |
Why?
| | Tissue Scaffolds | 1 | 2015 | 219 | 0.100 |
Why?
| | Antimetabolites | 1 | 2012 | 21 | 0.100 |
Why?
| | Photochemotherapy | 1 | 2013 | 39 | 0.090 |
Why?
| | Manifest Anxiety Scale | 1 | 2012 | 3 | 0.090 |
Why?
| | Patient Satisfaction | 1 | 2016 | 704 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1682 | 0.090 |
Why?
| | Quality of Life | 1 | 2024 | 3166 | 0.090 |
Why?
| | Cross-Over Studies | 1 | 2014 | 600 | 0.090 |
Why?
| | Melanins | 1 | 2011 | 17 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 52 | 0.090 |
Why?
| | Needles | 1 | 2012 | 62 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 338 | 0.090 |
Why?
| | Fluoresceins | 1 | 2011 | 48 | 0.090 |
Why?
| | Cattle | 1 | 2014 | 999 | 0.090 |
Why?
| | Elastin | 1 | 2011 | 79 | 0.090 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 2011 | 36 | 0.090 |
Why?
| | Self Efficacy | 1 | 2015 | 411 | 0.080 |
Why?
| | Cell Death | 1 | 2013 | 383 | 0.080 |
Why?
| | Biocompatible Materials | 1 | 2015 | 435 | 0.080 |
Why?
| | Lasers | 1 | 2011 | 132 | 0.080 |
Why?
| | Dextrans | 1 | 2011 | 86 | 0.080 |
Why?
| | Psychometrics | 1 | 2015 | 730 | 0.080 |
Why?
| | Immunoglobulin Fragments | 1 | 2010 | 11 | 0.080 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 131 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 474 | 0.080 |
Why?
| | Memory Disorders | 1 | 2012 | 193 | 0.080 |
Why?
| | Silicone Oils | 1 | 2011 | 34 | 0.080 |
Why?
| | Retreatment | 1 | 2010 | 77 | 0.080 |
Why?
| | Fovea Centralis | 1 | 2010 | 24 | 0.080 |
Why?
| | Equipment Safety | 1 | 2010 | 38 | 0.080 |
Why?
| | Electromagnetic Fields | 1 | 2010 | 37 | 0.080 |
Why?
| | Microscopy, Electron, Scanning | 4 | 2015 | 199 | 0.080 |
Why?
| | Physician-Patient Relations | 1 | 2015 | 581 | 0.080 |
Why?
| | Chromatography, Gel | 1 | 2010 | 129 | 0.080 |
Why?
| | Immunoglobulin Light Chains | 1 | 2010 | 51 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2012 | 231 | 0.080 |
Why?
| | Torque | 1 | 2010 | 81 | 0.080 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2010 | 85 | 0.080 |
Why?
| | Motivation | 1 | 2015 | 605 | 0.080 |
Why?
| | Molecular Weight | 1 | 2010 | 327 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 330 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2016 | 5988 | 0.080 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2010 | 81 | 0.080 |
Why?
| | Aptamers, Nucleotide | 1 | 2010 | 85 | 0.080 |
Why?
| | Protein Multimerization | 1 | 2011 | 213 | 0.080 |
Why?
| | Endocrine System Diseases | 1 | 2009 | 35 | 0.080 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 593 | 0.070 |
Why?
| | Cell Separation | 1 | 2010 | 307 | 0.070 |
Why?
| | Tissue Donors | 1 | 2012 | 424 | 0.070 |
Why?
| | Fluorescent Dyes | 1 | 2011 | 329 | 0.070 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 321 | 0.070 |
Why?
| | Reference Values | 1 | 2010 | 797 | 0.070 |
Why?
| | Suture Techniques | 1 | 2010 | 131 | 0.070 |
Why?
| | Risk Assessment | 2 | 2020 | 3637 | 0.070 |
Why?
| | Sodium Chloride | 1 | 2009 | 141 | 0.070 |
Why?
| | Vasoconstriction | 1 | 2010 | 217 | 0.070 |
Why?
| | Communication | 1 | 2015 | 961 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 416 | 0.070 |
Why?
| | Ocular Motility Disorders | 1 | 2009 | 41 | 0.070 |
Why?
| | Amphetamine-Related Disorders | 1 | 2009 | 47 | 0.070 |
Why?
| | Choroidal Neovascularization | 1 | 2009 | 57 | 0.070 |
Why?
| | Retinal Vein Occlusion | 1 | 2008 | 13 | 0.070 |
Why?
| | Chondroitin | 1 | 2008 | 6 | 0.070 |
Why?
| | Fluorescein | 1 | 2008 | 24 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 1 | 2011 | 576 | 0.070 |
Why?
| | Risk Factors | 3 | 2018 | 10699 | 0.070 |
Why?
| | Methamphetamine | 1 | 2009 | 68 | 0.070 |
Why?
| | Microvilli | 1 | 2008 | 75 | 0.070 |
Why?
| | Rupture | 1 | 2008 | 91 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 850 | 0.070 |
Why?
| | Lymphocyte Count | 1 | 2008 | 164 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 964 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 846 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 178 | 0.070 |
Why?
| | Cell Line | 1 | 2013 | 2879 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 7155 | 0.060 |
Why?
| | Central Nervous System Stimulants | 1 | 2009 | 182 | 0.060 |
Why?
| | Neuropsychological Tests | 1 | 2012 | 1129 | 0.060 |
Why?
| | Mice | 6 | 2016 | 18329 | 0.060 |
Why?
| | Mice, Inbred BALB C | 3 | 2015 | 1253 | 0.060 |
Why?
| | United States | 5 | 2022 | 15876 | 0.060 |
Why?
| | Molteno Implants | 1 | 2006 | 2 | 0.060 |
Why?
| | Perioperative Care | 2 | 2019 | 230 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2877 | 0.060 |
Why?
| | Uveal Diseases | 1 | 2006 | 6 | 0.060 |
Why?
| | Conjunctivitis | 1 | 2006 | 30 | 0.060 |
Why?
| | Scleral Buckling | 1 | 2006 | 15 | 0.060 |
Why?
| | Glucosyltransferases | 1 | 2006 | 4 | 0.060 |
Why?
| | Sweat Gland Neoplasms | 1 | 2006 | 8 | 0.060 |
Why?
| | Sutures | 1 | 2006 | 64 | 0.060 |
Why?
| | Eyelid Neoplasms | 1 | 2006 | 10 | 0.060 |
Why?
| | Lymphocytes | 1 | 2008 | 382 | 0.060 |
Why?
| | Motorcycles | 1 | 2005 | 7 | 0.060 |
Why?
| | Glycosylation | 1 | 2006 | 172 | 0.060 |
Why?
| | Geniculate Bodies | 1 | 2025 | 22 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 14 | 0.060 |
Why?
| | Fundus Oculi | 1 | 2025 | 88 | 0.060 |
Why?
| | Uncertainty | 1 | 2026 | 144 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1983 | 0.060 |
Why?
| | Forecasting | 1 | 2007 | 388 | 0.060 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2006 | 76 | 0.050 |
Why?
| | Treatment Failure | 1 | 2006 | 363 | 0.050 |
Why?
| | Prevalence | 1 | 2012 | 2815 | 0.050 |
Why?
| | Syndrome | 1 | 2006 | 380 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2023 | 2111 | 0.050 |
Why?
| | Accidents, Traffic | 1 | 2005 | 190 | 0.050 |
Why?
| | Vietnam | 1 | 2023 | 30 | 0.050 |
Why?
| | Materials Testing | 2 | 2015 | 354 | 0.050 |
Why?
| | Optical Imaging | 2 | 2015 | 64 | 0.050 |
Why?
| | Sleep | 2 | 2023 | 901 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 329 | 0.050 |
Why?
| | Incidence | 1 | 2010 | 2870 | 0.050 |
Why?
| | Neurology | 1 | 2024 | 110 | 0.050 |
Why?
| | Injections, Intraocular | 2 | 2014 | 14 | 0.050 |
Why?
| | Photography | 1 | 2023 | 115 | 0.050 |
Why?
| | Reoperation | 1 | 2006 | 629 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2096 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2430 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 1050 | 0.040 |
Why?
| | Age Factors | 1 | 2009 | 3313 | 0.040 |
Why?
| | Manometry | 1 | 2021 | 97 | 0.040 |
Why?
| | Prognosis | 2 | 2020 | 4278 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2022 | 322 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2006 | 1165 | 0.040 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2018 | 14 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 148 | 0.040 |
Why?
| | Axial Length, Eye | 1 | 2018 | 16 | 0.030 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.030 |
Why?
| | Drug Resistance | 1 | 2018 | 153 | 0.030 |
Why?
| | Adolescent | 4 | 2019 | 22281 | 0.030 |
Why?
| | Refraction, Ocular | 1 | 2018 | 47 | 0.030 |
Why?
| | Algorithms | 1 | 2026 | 1834 | 0.030 |
Why?
| | Pupil | 1 | 2016 | 22 | 0.030 |
Why?
| | Rats | 2 | 2016 | 5592 | 0.030 |
Why?
| | Biomimetics | 1 | 2016 | 40 | 0.030 |
Why?
| | Nerve Regeneration | 1 | 2016 | 56 | 0.030 |
Why?
| | Neurites | 1 | 2016 | 50 | 0.030 |
Why?
| | Fluoroquinolones | 1 | 2016 | 44 | 0.030 |
Why?
| | Prednisolone | 1 | 2016 | 66 | 0.030 |
Why?
| | Color Perception Tests | 1 | 2015 | 3 | 0.030 |
Why?
| | Slit Lamp | 1 | 2015 | 3 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 71 | 0.030 |
Why?
| | Opossums | 1 | 2015 | 9 | 0.030 |
Why?
| | Medical Device Legislation | 1 | 2015 | 3 | 0.030 |
Why?
| | Anterior Eye Segment | 1 | 2015 | 10 | 0.030 |
Why?
| | Device Approval | 1 | 2015 | 19 | 0.030 |
Why?
| | Color | 1 | 2015 | 81 | 0.030 |
Why?
| | Muscle, Smooth | 1 | 2016 | 151 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2015 | 121 | 0.030 |
Why?
| | Academies and Institutes | 1 | 2015 | 60 | 0.030 |
Why?
| | Axons | 1 | 2016 | 201 | 0.030 |
Why?
| | Device Removal | 1 | 2016 | 142 | 0.030 |
Why?
| | Membrane Lipids | 1 | 2015 | 83 | 0.030 |
Why?
| | Validation Studies as Topic | 1 | 2014 | 23 | 0.030 |
Why?
| | Drug Utilization | 1 | 2015 | 166 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2015 | 97 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 4085 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 392 | 0.030 |
Why?
| | Quality Control | 1 | 2014 | 163 | 0.030 |
Why?
| | Reference Standards | 1 | 2014 | 177 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2014 | 194 | 0.030 |
Why?
| | Corneal Stroma | 1 | 2013 | 24 | 0.020 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2013 | 29 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2013 | 79 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2013 | 150 | 0.020 |
Why?
| | Finite Element Analysis | 1 | 2012 | 67 | 0.020 |
Why?
| | Attitude to Health | 1 | 2015 | 434 | 0.020 |
Why?
| | Biological Availability | 1 | 2012 | 142 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 525 | 0.020 |
Why?
| | Permeability | 1 | 2012 | 168 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2012 | 168 | 0.020 |
Why?
| | Chronic Disease | 2 | 2008 | 1812 | 0.020 |
Why?
| | Massage | 1 | 2011 | 42 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 677 | 0.020 |
Why?
| | Drug Compounding | 1 | 2011 | 107 | 0.020 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2009 | 14 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2012 | 494 | 0.020 |
Why?
| | Particle Size | 1 | 2011 | 406 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5935 | 0.020 |
Why?
| | Ultrasonography | 1 | 2011 | 768 | 0.020 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 36 | 0.020 |
Why?
| | Mohs Surgery | 1 | 2006 | 29 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1906 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2006 | 222 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 778 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4254 | 0.010 |
Why?
| | Biopsy | 1 | 2006 | 1075 | 0.010 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2009 | 674 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1487 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 7180 | 0.010 |
Why?
| | Infant | 1 | 2010 | 10022 | 0.010 |
Why?
| | Child, Preschool | 1 | 2010 | 11774 | 0.010 |
Why?
| | Child | 1 | 2010 | 22537 | 0.000 |
Why?
|
|
Kahook's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|